| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Feb 2026 | 31 Jan 2026 |
| SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve the Unaudited (Standalone and Consolidated) Financial Results of the Company for the third quarter ended on 31st December 2025. Financial results for the quarter ended 31st December, 2025 Financial Results for the quarter ended 31st December, 2025 (As Per BSE Announcement Dated on:07.02.2026) | ||
| Board Meeting | 8 Nov 2025 | 3 Nov 2025 |
| SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2025 inter alia to consider and approve approval of Unaudited financial results for the quarter ended 30th September 2025 Approval of financial results for the quarter ended 30th September, 2025 (As per BSE Announcement dated on: 08.11.2025) | ||
| Board Meeting | 16 Oct 2025 | 16 Oct 2025 |
| Intimation under Regulation 30 of SEBI(LODR), Regulations, 2015 | ||
| Board Meeting | 9 Aug 2025 | 2 Aug 2025 |
| SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2025 inter alia to consider and approve the Unaudited (Standalone and Consolidated) Financial Results of the Company for the first quarter ended on 30th June 2025. Outcome of Board Meeting and Financial Results for the first quarter ended 30th June, 2025 (As Per BSE Announcement Dated on: 09/08/2025) | ||
| Board Meeting | 1 Jul 2025 | 1 Jul 2025 |
| Re-appointment of Mr. Vamsi Krishna Potluri (DIN:06956498) as Whole Time Director of the Company. | ||
| Board Meeting | 30 May 2025 | 23 May 2025 |
| SMS Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Audited Financial Results for the fourth quarter and year ended 2025. Approval of Financial results for the fourth quarter and year ended 31st March, 2025. (As per BSE Announcement Dated on 30/05/2025) | ||
| Board Meeting | 27 Mar 2025 | 27 Mar 2025 |
| Allotment of Equity shares pursuant to conversion of warrants. | ||
SMS Pharma added that it will submit its formal response to the USFDA within the stipulated timeline, in line with standard regulatory practice.
For the June quarter, SMS Pharma reported a 24.3% year-on-year jump in net profit to ₹20.49 crore, compared with ₹16.48 crore a year earlier.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
